May 27 2022




Recommendations

Risks to infants

There are no published harmful effects on breastfed infants whose mothers received ketorolac.

The only published study on this drug [1] includes ten women who in the immediate postpartum week received ketorolac 10 mg every six hours, which was measured repeatedly over a period of 48 hours the concentration of the substance in the milk. In four cases was not detected an appreciable level of ketorolac being equal to or below 5 ng / ml, while in the remaining, levels at two hours after administration of ketorolac ranged from 5.2 ng / ml and 7.3 ng / ml during the first day and slightly higher amounts during the second day of the study. At ten hours of the last dose, ketorolac was not detected in the milk of these six women. According to the calculations made??, the baby may eat up to 7.9 mcg per day (0.18% of the maternal dose).

Influence on breast

There are no published data on this.

Recommendations

Although considered compatible with breastfeeding, the U.S. labeling warns against breastfeeding during maternal treatment with ketorolac, both oral and parenteral administration.

It is probably prudent to replace a potentially toxic anti-inflammatory medicine, such as ketorolac, by a more safe drug.

References

1. Wischnik A, Manth SM, Lloyd J et al. The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. Eur J Clin Pharmacol. 1989, 36:521-4.

Warning of the manufacturer:

This drug is contraindicated during lactation.

Updated:21.02.08